Download PDFPDF
Dietary products used in infants for treatment and prevention of food allergy.
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Re: Dietary products used in infants for treatment and prevention of food allergy
    Dear Editor

    We agree with the letter from Professor Koletzko suggesting that more studies in this field are necessary (Arch Dis Child Rapid Response 6 June 2000). However, Table 4 of my study detailed all the data of the "other authors" and tried to make a mean among all such data. Since Sampson et al documented a 0% prevelence of sensitisation to soy, we concluded that about "80-100%" of children.


    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Response to Prof. Analado Cantani

    The comment of Dr. Cantani (Arch Dis Child rapid response, 2 June 2000) is interesting and reemphasizes our conclusion drawn in the joint statement of ESPGHAN and ESPACI (Arch Dis Child 1999;81:80-84) that in view of controversial judgements more studies are required to further elucidate the effects of soy protein based formulas in infants with food allergies. Although Cantani claims that 80-100% of infants with IgE media...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Dietary products used in infants for treatment and prevention of food allergy
    Dear Editor

    In a not cited paper published by Pediatric Allergy Immunology I have detailed everything about soy formulas (SFs). Children with atopic dermatitis fare well on SFs, those with colitis/enterocolitis have reactions to soy, but Burks demonstrated that these are not IgE-mediated, therefore it is improper to classify such reactions as allergenic.

    In Table 4, 19.8% of children (mean) reacted to SFs, but...

    Show More
    Conflict of Interest:
    None declared.